{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:27:07Z","timestamp":1787563627395,"version":"build-2736575974"},"reference-count":114,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T00:00:00Z","timestamp":1555977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline Biologicals SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.vaccine.2019.04.048","type":"journal-article","created":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T09:34:42Z","timestamp":1556184882000},"page":"3006-3021","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":107,"title":["Safety of AS03-adjuvanted influenza vaccines: A review of the evidence"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0022-7251","authenticated-orcid":false,"given":"Catherine","family":"Cohet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robbert","family":"van der Most","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Bauchau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafik","family":"Bekkat-Berkani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Mark","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3544-0682","authenticated-orcid":false,"given":"Anne","family":"Schuind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Tavares Da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rino","family":"Rappuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Gar\u00e7on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce L.","family":"Innis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.04.048_b0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/21645515.2016.1225635","article-title":"From discovery to licensure, the adjuvant System story","volume":"13","author":"Gar\u00e7on","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.04.048_b0010","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1586\/erv.11.192","article-title":"Development and evaluation of AS03, an adjuvant system containing \u03b1-tocopherol and squalene in an oil-in-water emulsion","volume":"11","author":"Gar\u00e7on","year":"2012","journal-title":"Exp Rev Vacc"},{"key":"10.1016\/j.vaccine.2019.04.048_b0015","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.vaccine.2011.01.011","article-title":"Adjuvant system AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity","volume":"29","author":"Morel","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.048_b0020","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1097\/INF.0b013e3181daf921","article-title":"Immunogenicity and safety of H5N1 A\/Vietnam\/1194\/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase II, randomized, open, controlled study","volume":"29","author":"D\u00edez-Domingo","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2019.04.048_b0025","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/infdis\/jiq174","article-title":"Immunogenicity profile of a 3.75-\u03bcg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial","volume":"203","author":"Heijmans","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.048_b0030","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1086\/652701","article-title":"Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1\/2 trial in adults","volume":"201","author":"Langley","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.048_b0035","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0140-6736(07)61297-5","article-title":"Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial","volume":"370","author":"Leroux-Roels","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.04.048_b0040","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10875-010-9490-6","article-title":"H5N1 influenza vaccine formulated with AS03A induces strong cross-reactive and polyfunctional CD4 T-cell responses","volume":"31","author":"Moris","year":"2011","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.vaccine.2019.04.048_b0045","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008409","article-title":"Seeking help: B cells adapting to flu variability","volume":"6","author":"van der Most","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2019.04.048_b0050","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.virusres.2013.05.006","article-title":"H5N1 vaccines in humans","volume":"178","author":"Baz","year":"2013","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2019.04.048_b0055","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.vaccine.2017.02.059","article-title":"Effectiveness of 2009 pandemic influenza A(H1N1) vaccines: a systematic review and meta-analysis","volume":"35","author":"Lansbury","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.048_b0060","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/infdis\/jiu173","article-title":"Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial","volume":"210","author":"Nolan","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.048_b0065","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S1473-3099(13)70046-X","article-title":"AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial","volume":"13","author":"McElhaney","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.048_b0070","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jama.2015.7916","article-title":"Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: a randomized clinical trial","volume":"314","author":"Jackson","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2019.04.048_b0075","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.vaccine.2017.02.057","article-title":"Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65 years of age and older: a phase II, observer-blind, randomized, controlled trial","volume":"35","author":"Madan","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.048_b0080","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.vaccine.2017.01.054","article-title":"Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: a phase I\/II, observer-blind, randomized, controlled trial","volume":"35","author":"Madan","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.048_b0085","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1016\/j.vaccine.2017.07.013","article-title":"Evaluation of a primary course of H9N2 vaccine with or without AS03 adjuvant in adults: a phase I\/II randomized trial","volume":"35","author":"Madan","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.048_b0090","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.vascn.2013.04.003","article-title":"Evaluation of C-reactive protein as an inflammatory biomarker in rabbits for vaccine nonclinical safety studies","volume":"68","author":"Destexhe","year":"2013","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.vaccine.2019.04.048_b0095","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/jat.3130","article-title":"Non-clinical safety and biodistribution of AS03-adjuvanted inactivated pandemic influenza vaccines","volume":"35","author":"Segal","year":"2015","journal-title":"J Appl Toxicol"},{"key":"10.1016\/j.vaccine.2019.04.048_b0100","unstructured":"GSK. Influenza A (H5N1) virus monovalent vaccine, adjuvanted. Vaccines and Related Biological Products Advisory Committee (VRBPAC) briefing document. November 14, 2012 2012. 23\/04\/2018. https:\/\/wayback.archive-it.org\/7993\/20170113080316\/http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/BloodVaccinesandOtherBiologics\/VaccinesandRelatedBiologicalProductsAdvisoryCommittee\/UCM333630.pdf."},{"key":"10.1016\/j.vaccine.2019.04.048_b0105","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.yrtph.2015.06.003","article-title":"Effects of adjuvant systems on the cardiovascular and respiratory functions in telemetered conscious dogs and anaesthetised rats","volume":"73","author":"Segal","year":"2015","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.vaccine.2019.04.048_b0110","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1080\/21645515.2016.1227518","article-title":"Evaluation of the potential effects of AS03-adjuvanted A(H1N1)pdm09 vaccine administration on the central nervous system of non-primed and A(H1N1)pdm09-primed cotton rats","volume":"13","author":"Planty","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.04.048_b0115","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/infdis\/jir172","article-title":"Dose-sparing H5N1 A\/Indonesia\/05\/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study","volume":"203","author":"Langley","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.048_b0120","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.1016\/j.vaccine.2009.07.102","article-title":"Immunogenicity and tolerability of an AS03A-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults","volume":"27","author":"Chu","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.048_b0125","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.vaccine.2008.02.068","article-title":"Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial","volume":"26","author":"R\u00fcmke","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.048_b0130","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/infdis\/jir641","article-title":"Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant","volume":"205","author":"Ferguson","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.048_b0135","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1016\/j.vaccine.2013.07.007","article-title":"Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial","volume":"31","author":"Yang","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.048_b0140","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/1471-2334-12-279","article-title":"A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine","volume":"12","author":"Langley","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.048_b0145","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.vaccine.2009.12.014","article-title":"Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial","volume":"28","author":"Roman","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.048_b0150","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/irv.12295","article-title":"Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination","volume":"9","author":"D\u00edez-Domingo","year":"2015","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2019.04.048_b0155","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/infdis\/jiu548","article-title":"AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2\/3 randomized, placebo-controlled, observer-blinded trial","volume":"211","author":"Kosalaraksa","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.048_b0160","doi-asserted-by":"crossref","first-page":"c2649","DOI":"10.1136\/bmj.c2649","article-title":"Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study","volume":"340","author":"Waddington","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2019.04.048_b0165","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.vaccine.2013.11.031","article-title":"An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1\/2009 influenza vaccines in children 10\u201317 years of age","volume":"32","author":"Poder","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.048_b0170","doi-asserted-by":"crossref","first-page":"5837","DOI":"10.1016\/j.vaccine.2010.06.065","article-title":"Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6\u201335 months","volume":"28","author":"Carmona","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.048_b0175","unstructured":"European Medicines Agency. CHMP recommendations for the pharmacovigilance plan as part of the Risk Management Plan to be submitted with the Marketing Authorisation Application for a pandemic influenza vaccine. Revision 1.1. EMEA\/359381\/2009 2009. 17 December 2018. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2010\/01\/WC500051739.pdf."},{"key":"10.1016\/j.vaccine.2019.04.048_b0180","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.4161\/21645515.2014.972149","article-title":"Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials","volume":"10","author":"Vaughn","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.04.048_b0185","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.4161\/hv.28743","article-title":"A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months","volume":"10","author":"Carmona Martinez","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.04.048_b0190","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1186\/1471-2334-14-425","article-title":"Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older","volume":"14","author":"Couch","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.048_b0195","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/1471-2334-13-348","article-title":"Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial","volume":"13","author":"R\u00fcmke","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.048_b0200","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1080\/21645515.2015.1043501","article-title":"Safety assessment of adjuvanted vaccines: methodological considerations","volume":"11","author":"Tavares Da Silva","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.04.048_b0205","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.vaccine.2017.12.019","article-title":"How close are countries of the WHO European region to achieving the goal of vaccinating 75% of key risk groups against influenza? results from national surveys on seasonal influenza vaccination programmes, 2008\/2009 to 2014\/2015","volume":"36","author":"Jorgensen","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.048_b0210","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1586\/14760584.2015.1091733","article-title":"The costs and effectiveness of large phase III pre-licensure vaccine clinical trials","volume":"14","author":"Black","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.04.048_b0215","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001912","article-title":"Safety of AS03-adjuvanted split-virion H1N1 (2009) pandemic influenza vaccine: a prospective cohort study","volume":"3","author":"Nazareth","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2019.04.048_b0220","doi-asserted-by":"crossref","first-page":"e7594","DOI":"10.1136\/bmj.e7594","article-title":"Risk of presentation to hospital with epileptic seizures after vaccination with monovalent AS03 adjuvanted pandemic A\/H1N1 2009 influenza vaccine (Pandemrix): self controlled case series study","volume":"345","author":"Arnheim-Dahlstr\u00f6m","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2019.04.048_b0225","unstructured":"European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. EU PAS Register: study number EUPAS6817. 2017. http:\/\/www.encepp.eu\/encepp\/viewResource.htm?id=12979#."},{"key":"10.1016\/j.vaccine.2019.04.048_b0230","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.3201\/eid2407.161783","article-title":"Registry cohort study to determine risk for multiple sclerosis after vaccination for pandemic influenza A(H1N1) with Arepanrix, Manitoba, Canada","volume":"24","author":"Mahmud","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.048_b0235","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/joim.12150","article-title":"Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up","volume":"275","author":"Persson","year":"2014","journal-title":"J Intern Med"},{"key":"10.1016\/j.vaccine.2019.04.048_b0240","doi-asserted-by":"crossref","first-page":"e38563","DOI":"10.1371\/journal.pone.0038563","article-title":"Short and long-term safety of the 2009 AS03-adjuvanted pandemic vaccine","volume":"7","author":"De Serres","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.04.048_b0245","unstructured":"ClinicalTrials.gov. H1N1 vaccine safety in Manitoba, Canada. ClinicalTrials.gov Identifier: NCT01421251. 2012. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01421251?term=NCT01421251&rank=1."},{"key":"10.1016\/j.vaccine.2019.04.048_b0250","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1017\/cjn.2016.291","article-title":"Pandemic H1N1 vaccination and incidence of acute disseminated encephalomyelitis in Manitoba","volume":"43","author":"Jackson","year":"2016","journal-title":"Can J Neurol Sci"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2019.04.048_b0255","doi-asserted-by":"crossref","first-page":"B6","DOI":"10.1016\/j.vaccine.2015.03.026","article-title":"The narcolepsy-pandemic influenza story: can the truth ever be unraveled?","volume":"33","author":"Sturkenboom","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.048_b0260","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/21645515.2015.1068486","article-title":"Pandemrix\u2122 and narcolepsy: a critical appraisal of the observational studies","volume":"12","author":"Verstraeten","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.04.048_b0265","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.smrv.2017.06.006","article-title":"Incidence of narcolepsy after H1N1 influenza and vaccinations: systematic review and meta-analysis","volume":"38","author":"Sarkanen","year":"2018","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.vaccine.2019.04.048_b0270","doi-asserted-by":"crossref","first-page":"e108489","DOI":"10.1371\/journal.pone.0108489","article-title":"Risk of narcolepsy associated with inactivated adjuvanted (AS03) A\/H1N1 (2009) pandemic influenza vaccine in Quebec","volume":"9","author":"Montplaisir","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.04.048_b0275","first-page":"406","article-title":"Applying the test-negative design to vaccine safety studies: risk of narcolepsy associated with A\/H1N1 (2009) pandemic influenza vaccination in Quebec [abstract 713]","volume":"24","author":"Cohet","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2019.04.048_b0280","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES2014.19.36.20900","article-title":"Did narcolepsy occur following administration of AS03-adjuvanted A(H1N1) pandemic vaccine in Ontario, Canada? a review of post-marketing safety surveillance data","volume":"19","author":"Harris","year":"2014","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2019.04.048_b0285","doi-asserted-by":"crossref","first-page":"6202","DOI":"10.1016\/j.vaccine.2018.08.008","article-title":"Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines - multi-country assessment","volume":"36","author":"Weibel","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.048_b0290","doi-asserted-by":"crossref","first-page":"e0149289","DOI":"10.1371\/journal.pone.0149289","article-title":"Application of probabilistic multiple-bias analyses to a cohort- and a case-control study on the association between Pandemrix and narcolepsy","volume":"11","author":"Bollaerts","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.04.048_b0295","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1586\/14760584.2016.1164045","article-title":"Pandemic influenza vaccine & narcolepsy: simulations on the potential impact of bias","volume":"15","author":"Wijnans","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.04.048_b0300","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ana.23799","article-title":"Decreased incidence of childhood narcolepsy 2 years after the 2009 H1N1 winter flu pandemic","volume":"73","author":"Han","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.vaccine.2019.04.048_b0305","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/ana.22587","article-title":"Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China","volume":"70","author":"Han","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.vaccine.2019.04.048_b0310","doi-asserted-by":"crossref","first-page":"e1003880","DOI":"10.1371\/journal.pgen.1003880","article-title":"Genome wide analysis of narcolepsy in China implicates novel immune loci and reveals changes in association prior to versus after the 2009 H1N1 influenza pandemic","volume":"9","author":"Han","year":"2013","journal-title":"PLoS Genet"},{"key":"10.1016\/j.vaccine.2019.04.048_b0315","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.5665\/sleep.5060","article-title":"Incidence of narcolepsy in Germany","volume":"38","author":"Oberle","year":"2015","journal-title":"Sleep"},{"key":"10.1016\/j.vaccine.2019.04.048_b0320","first-page":"524","article-title":"Increased incidence of narcolepsy after the 2009 H1N1 pandemic and vaccination campaign in Taiwan [abstract 901]","volume":"25","author":"Huang","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2019.04.048_b0325","doi-asserted-by":"crossref","first-page":"e0151575","DOI":"10.1371\/journal.pone.0151575","article-title":"Twin peaks: A\/H1N1 pandemic influenza virus infection and vaccination in Norway, 2009\u20132010","volume":"11","author":"Van Effelterre","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.04.048_b0330","first-page":"1012","article-title":"HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients","volume":"20","author":"Mignot","year":"1997","journal-title":"Sleep"},{"key":"10.1016\/j.vaccine.2019.04.048_b0335","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bbi.2015.05.003","article-title":"A polymorphism in CCR1\/CCR3 is associated with narcolepsy","volume":"49","author":"Toyoda","year":"2015","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.vaccine.2019.04.048_b0340","first-page":"14","article-title":"Epidemiology and pathophysiology of childhood narcolepsy","volume":"25","author":"Dye","year":"2018","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.vaccine.2019.04.048_b0345","doi-asserted-by":"crossref","first-page":"32899","DOI":"10.1038\/srep32899","article-title":"Incomplete immune response to coxsackie B viruses associates with early autoimmunity against insulin","volume":"6","author":"Ashton","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2019.04.048_b0350","unstructured":"European Medicines Agency. Assessment report. Pandemrix. 2016. EMA\/CHMP\/566359\/2015. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000832\/WC500208569.pdf."},{"key":"10.1016\/j.vaccine.2019.04.048_b0355","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41586-018-0540-1","article-title":"T cells in patients with narcolepsy target self-antigens of hypocretin neurons","volume":"562","author":"Latorre","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2019.04.048_b0360","doi-asserted-by":"crossref","first-page":"E12323","DOI":"10.1073\/pnas.1818150116","article-title":"Autoimmunity to hypocretin and molecular mimicry to flu in type 1 narcolepsy","volume":"115","author":"Luo","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2019.04.048_b0365","doi-asserted-by":"crossref","first-page":"10956","DOI":"10.1073\/pnas.1603325113","article-title":"CD8 T cell-mediated killing of orexinergic neurons induces a narcolepsy-like phenotype in mice","volume":"113","author":"Bernard-Valnet","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2019.04.048_b0370","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aab2354","article-title":"et al.Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2","volume":"7","author":"Ahmed","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2019.04.048_b0375","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad2353","article-title":"Comment on \u201cAntibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2\u201d","volume":"7","author":"Vassalli","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2019.04.048_b0380","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsw056","article-title":"Antibodies against hypocretin receptor 2 are rare in narcolepsy","volume":"40","author":"Giannoccaro","year":"2017","journal-title":"Sleep"},{"key":"10.1016\/j.vaccine.2019.04.048_b0385","doi-asserted-by":"crossref","first-page":"9467","DOI":"10.1016\/j.vaccine.2011.10.029","article-title":"Risk of convulsions in children after monovalent H1N1 (2009) and trivalent influenza vaccines: a database study","volume":"29","author":"Stowe","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.048_b0390","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1186\/s12879-015-1263-7","article-title":"Febrile seizures after 2009 influenza A (H1N1) vaccination and infection: a nationwide registry-based study","volume":"15","author":"Bakken","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.048_b0395","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2012.7342","article-title":"Risk of Guillain-Barr\u00e9 syndrome following H1N1 influenza vaccination in Quebec","volume":"308","author":"De Wals","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2019.04.048_b0400","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/pds.3638","article-title":"Risk of Guillain-Barr\u00e9 syndrome following pandemic influenza A(H1N1) 2009 vaccination in Germany","volume":"23","author":"Prestel","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2019.04.048_b0405","doi-asserted-by":"crossref","first-page":"d3908","DOI":"10.1136\/bmj.d3908","article-title":"Guillain-Barr\u00e9 syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe","volume":"343","author":"Dieleman","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2019.04.048_b0410","doi-asserted-by":"crossref","first-page":"e82222","DOI":"10.1371\/journal.pone.0082222","article-title":"Guillain-Barr\u00e9 syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in Europe","volume":"9","author":"Romio","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.04.048_b0415","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/aje\/kwr072","article-title":"Guillain-Barr\u00e9 syndrome, influenzalike illnesses, and influenza vaccination during seasons with and without circulating A\/H1N1 viruses","volume":"174","author":"Grimaldi-Bensouda","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2019.04.048_b0420","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1136\/archdischild-2013-304475","article-title":"Pandemic A\/H1N1 2009 influenza vaccination, preceding infections and clinical findings in UK children with Guillain-Barr\u00e9 syndrome","volume":"99","author":"Verity","year":"2014","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2019.04.048_b0425","doi-asserted-by":"crossref","first-page":"7878","DOI":"10.1016\/j.vaccine.2011.08.069","article-title":"Guillain-Barr\u00e9 syndrome and H1N1 (2009) pandemic influenza vaccination using an AS03 adjuvanted vaccine in the United Kingdom: self-controlled case series","volume":"29","author":"Andrews","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.048_b0430","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1016\/j.vaccine.2013.06.032","article-title":"International collaboration to assess the risk of Guillain Barr\u00e9 syndrome following influenza A (H1N1) 2009 monovalent vaccines","volume":"31","author":"Dodd","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.048_b0435","doi-asserted-by":"crossref","first-page":"7123","DOI":"10.1016\/j.vaccine.2012.09.032","article-title":"Autoimmune disorders after immunisation with influenza A\/H1N1 vaccines with and without adjuvant: EudraVigilance data and literature review","volume":"30","author":"Isai","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.048_b0440","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/cid\/ciu005","article-title":"Guillain-Barr\u00e9 syndrome, influenza, and influenza vaccination: the epidemiologic evidence","volume":"58","author":"Vellozzi","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.048_b0445","doi-asserted-by":"crossref","first-page":"6402","DOI":"10.1016\/j.vaccine.2011.04.026","article-title":"Anaphylaxis following H1N1 pandemic vaccines: safety data in perspective","volume":"29","author":"Tavares","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.048_b0450","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1016\/j.vaccine.2013.10.033","article-title":"Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A\/H1N1 (H1N1pdm09) vaccine","volume":"31","author":"Rouleau","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.048_b0455","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/ndt\/gfr278","article-title":"Immune response to an adjuvanted influenza A H1N1 vaccine (Pandemrix\u00ae) in renal transplant recipients","volume":"27","author":"Brakemeier","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.vaccine.2019.04.048_b0460","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1111\/j.1600-6143.2011.03743.x","article-title":"Impact of adjuvanted H1N1 vaccine on cell-mediated rejection in heart transplant recipients","volume":"11","author":"Schaffer","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.vaccine.2019.04.048_b0465","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1111\/j.1600-6143.2011.03604.x","article-title":"De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients","volume":"11","author":"Katerinis","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.vaccine.2019.04.048_b0470","doi-asserted-by":"crossref","first-page":"e009264","DOI":"10.1136\/bmjopen-2015-009264","article-title":"Effect of the adjuvanted (AS03) A\/H1N1 2009 pandemic influenza vaccine on the risk of rejection in solid organ transplant recipients in England: a self-controlled case series","volume":"6","author":"Cohet","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2019.04.048_b0475","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/QCO.0b013e328355a79b","article-title":"Influenza vaccines in the setting of solid-organ transplantation: are they safe?","volume":"25","author":"Avery","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.048_b0480","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/MOT.0b013e3283592622","article-title":"Influenza vaccination in solid-organ transplant recipients","volume":"17","author":"Cordero","year":"2012","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.vaccine.2019.04.048_b0485","doi-asserted-by":"crossref","first-page":"6358","DOI":"10.1016\/j.vaccine.2011.04.114","article-title":"Pregnancy and safety outcomes in women vaccinated with an AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine during pregnancy: a prospective cohort study","volume":"29","author":"Tavares","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.048_b0490","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejogrb.2014.04.015","article-title":"2009 A\/H1N1 influenza vaccination in pregnancy: uptake and pregnancy outcomes \u2013 a historical cohort study","volume":"178","author":"Cleary","year":"2014","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.vaccine.2019.04.048_b0495","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/bdra.23243","article-title":"Adjuvanted A\/H1N1 (2009) influenza vaccination during pregnancy: description of a prospective cohort and spontaneously reported pregnancy-related adverse reactions in the Netherlands","volume":"100","author":"de Vries","year":"2014","journal-title":"Birth Defect Res A Clin Mol Teratol"},{"key":"10.1016\/j.vaccine.2019.04.048_b0500","doi-asserted-by":"crossref","first-page":"e2794","DOI":"10.1136\/bmj.e2794","article-title":"Vaccination against pandemic A\/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark","volume":"344","author":"Pasternak","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2019.04.048_b0505","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1207210","article-title":"Risk of fetal death after pandemic influenza virus infection or vaccination","volume":"368","author":"H\u00e5berg","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.04.048_b0510","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1111\/j.1471-0528.2012.03470.x","article-title":"Vaccination against H1N1 influenza with Pandemrix\u00ae during pregnancy and delivery outcome: a Swedish register study","volume":"119","author":"K\u00e4ll\u00e9n","year":"2012","journal-title":"BJOG"},{"key":"10.1016\/j.vaccine.2019.04.048_b0515","doi-asserted-by":"crossref","first-page":"h5585","DOI":"10.1136\/bmj.h5585","article-title":"Maternal vaccination against H1N1 influenza and offspring mortality: population based cohort study and sibling design","volume":"351","author":"Ludvigsson","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2019.04.048_b0520","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1016\/j.vaccine.2012.04.081","article-title":"A(H1N1)v2009: a controlled observational prospective cohort study on vaccine safety in pregnancy","volume":"30","author":"Oppermann","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.048_b0525","doi-asserted-by":"crossref","first-page":"848","DOI":"10.7326\/M16-0139","article-title":"Risk for congenital malformation with H1N1 influenza vaccine: a cohort study with sibling analysis","volume":"165","author":"Ludvigsson","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2019.04.048_b0530","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.2105\/AJPH.2011.300606","article-title":"H1N1 influenza vaccination during pregnancy and fetal and neonatal outcomes","volume":"102","author":"Fell","year":"2012","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2019.04.048_b0535","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1093\/infdis\/jis487","article-title":"Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology","volume":"206","author":"Beck","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.048_b0540","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/irv.12243","article-title":"HIV virological suppression influences response to the AS03-adjuvanted monovalent pandemic influenza A H1N1 vaccine in HIV-infected children","volume":"8","author":"Leahy","year":"2014","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2019.04.048_b0545","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/2047-783X-16-7-289","article-title":"Acceptance and tolerability of an adjuvanted nH1N1 vaccine in HIV-infected patients in the Cologne-Bonn cohort","volume":"16","author":"Steffens","year":"2011","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.vaccine.2019.04.048_b0550","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/annonc\/mdr141","article-title":"Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and\/or targeted therapy: the VACANCE study","volume":"23","author":"Rousseau","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.vaccine.2019.04.048_b0555","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/ejh.12094","article-title":"Adjuvanted influenza a (H1N1) 2009 vaccine in patients with hematological diseases: good safety and immunogenicity even in chemotherapy-treated patients","volume":"90","author":"Cherif","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.vaccine.2019.04.048_b0560","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/infdis\/jiq014","article-title":"Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England","volume":"203","author":"Andrews","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.048_b0565","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3851\/IMP2103","article-title":"Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine","volume":"17","author":"Siegrist","year":"2012","journal-title":"Antivir Ther"},{"key":"10.1016\/j.vaccine.2019.04.048_b0570","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3389\/fimmu.2017.01760","article-title":"AS03- and MF59-adjuvanted influenza vaccines in children","volume":"8","author":"Wilkins","year":"2017","journal-title":"Front Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19305225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19305225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:32:40Z","timestamp":1759401160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19305225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":114,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0264410X19305225"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.048","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of AS03-adjuvanted influenza vaccines: A review of the evidence","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}